

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)
Policy No:	APC 501-2020
Date of Issue	October 2020
Review Date:	<p><i>The recommendation made by the APC can be reviewed prior to the review date when new published evidence or national guidance becomes available. A review can be requested via email to the APC secretary.</i></p> <p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal</i></p>
<p>Recommendations: The Area Prescribing Committee recommends avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure in line with NICE guidance (NICE TA 626)</p> <p>Avatrombopag is a payment by results excluded medicine and will be considered RED on the traffic light system. Prescribers will be required to complete a blueteq form at initiation</p> <p>Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA626 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure https://www.nice.org.uk/guidance/ta626 	
Date taken to Area Prescribing Committee	7 th October 2020
Agreed by APC members	16 th October 2020